Published 2022 | Version v1
Publication Metadata-only

Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy

Ferro M.
Tataru O. S.
Musi G.
Lucarelli G.
Abu Farhan A. R.
Cantiello F.
Damiano R.
Hurle R.
Contieri R.
Busetto G. M.
Carrieri G.
Cormio L.
Del Giudice F.
Sciarra A.
Perdona S.
Borghesi M.
Terrone C.
La Civita E.
Bove P.
Autorino R.
Muto M.
Crisan N.
Marchioni M.
Schips L.
Soria F.
Terracciano D.
Papalia R.
Crocetto F.
Barone B.
Russo G. I.
Luzzago S.
Ludovico G. M.
Vartolomei M. D.
Mistretta F. A.
Mirone V.
de Cobelli O.
Others:
Ferro, M.
Tataru, O. S.
Musi, G.
Lucarelli, G.
Abu Farhan, A. R.
Cantiello, F.
Damiano, R.
Hurle, R.
Contieri, R.
Busetto, G. M.
Carrieri, G.
Cormio, L.
Del Giudice, F.
Sciarra, A.
Perdona, S.
Borghesi, M.
Terrone, C.
La Civita, E.
Bove, P.
Autorino, R.
Muto, M.
Crisan, N.
Marchioni, M.
Schips, L.
Soria, F.
Terracciano, D.
Papalia, R.
Crocetto, F.
Barone, B.
Russo, G. I.
Luzzago, S.
Ludovico, G. M.
Vartolomei, M. D.
Mistretta, F. A.
Mirone, V.
de Cobelli, O.

Description

Background: A systemic inflammatory marker, the modified Glasgow prognostic score (mGPS), could predict outcomes in non-muscle-invasive bladder cancer (NIMBC). We aimed to investigate the predictive power of mGPS in oncological outcomes in HG/G3 T1 NMIBC patients undergoing Bacillus Calmette–Guérin (BCG) therapy. Methods: We retrospectively reviewed patient's medical data from multicenter institutions. A total of 1382 patients with HG/G3 T1 NMIBC have been administered adjuvant intravesical BCG therapy, every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months. The analysis of mGPS for recurrence and progression was performed using multivariable and univariable Cox regression models. Results: During follow-up, 659 patients (47.68%) suffered recurrence, 441 (31.91%) suffered progression, 156 (11.28%) died of all causes, and 67 (4.84%) died of bladder cancer. At multivariable analysis, neutrophil to lymphocyte ratio [hazard ratio (HR): 7.471; p = 0.0001] and erythrocyte sedimentation rate (ESR) (HR: 0.706; p = 0.006 were significantly associated with recurrence. mGPS has no statistical significance for progression (p = 0.076). Kaplan–Meier survival analysis showed a significant difference in survival among patients from different mGPS subgroups. Five-year OS was 93% (CI 95% 92–94), in patients with mGPS 0, 82.2% (CI 95% 78.9–85.5) in patients with mGPS 1 and 78.1% (CI 95% 60.4–70) in mGPS 2 patients. Five-year CSS was 98% (CI 95% 97–99) in patients with mGPS 0, 90% (CI 95% 87–94) in patients with mGPS 1, and 100% in mGPS 2 patients. Limitations are applicable to a retrospective study. Conclusions: mGPS may have the potential to predict recurrence in HG/G3 T1 NMIBC patients, but more prospective, with large cohorts, studies are needed to study the influence of systemic inflammatory markers in prediction of outcomes in NMIBC for a definitive conclusion.

Additional details

Identifiers Origin repository
Created:
February 14, 2024
Modified:
February 14, 2024